"1973年藤田啓介が開設した日本で最大規模の病床数の大学病院（愛知県名古屋市緑区、豊明市）です。ロボット手術を得意とし、ダビンチ、hinotori、ROSAなど最新のロボットを使用しています。愛知県指定の高度救命救急センターであり、３次救急医療施設として24時間体制で医療を提供しています。精神科では、保険適用となっているうつ病への反復経頭蓋磁気刺激（repetitive Transcranial Magnetic Stimulation; rTMS）TMS治療も行っています。2022年1月24日(月)より新型コロナワクチン追加接種（３回目接種）の大規模接種会場となっています。"

During the past decade, Fujita Health University Hospital conducted 72 clinical trials. In the 10-year time frame, 72 clinical trials started and 20 clinical trials were completed, i.e. on average, 27.8% percent of trials that started reached the finish line to date. In the past 5 years, 46 clinical trials started and 17 clinical trials were completed. i.e. 37% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fujita Health University Hospital" #1 sponsor was "Janssen Research & Development, LLC" with 8 trials, followed by "Boehringer Ingelheim" with 7 trials sponsored, "Janssen Pharmaceutical K.K." with 5 trials sponsored, "Takeda" with 5 trials sponsored and "Hoffmann-La Roche" with 5 trials sponsored. Other sponsors include 45 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fujita Health University Hospital" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Solasia Pharma K.K." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 24 trials.

According to Clinical.Site data, the most researched conditions in "Fujita Health University Hospital" are "Schizophrenia" (4 trials), "Ulcerative Colitis" (4 trials), "Non-small Cell Lung Cancer" (3 trials), "Urinary Bladder Neoplasms" (3 trials) and "ALK-positive Advanced NSCLC" (2 trials). Many other conditions were trialed in "Fujita Health University Hospital" in a lesser frequency.

Most popular intervention types in "Fujita Health University Hospital" are "Drug" (64 trials), "Other" (10 trials), "Biological" (6 trials), "Device" (5 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "Cisplatin" (3 trials), "Docetaxel" (3 trials), "Ustekinumab" (3 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Fujita Health University Hospital" are 76 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Fujita Health University Hospital". undefined are not yet recruiting, 32 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Fujita Health University Hospital, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Fujita Health University Hospital, 4 "Phase 1" clinical trials were conducted, 22 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 4 trials that are defined as “Not Applicable".